Acellular Dermal Matrix(SureDerm BCS) in Breast-Conserving Surgery for Breast Cancer Patients

NCT ID: NCT07345026

Last Updated: 2026-01-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

116 participants

Study Classification

INTERVENTIONAL

Study Start Date

2026-01-08

Study Completion Date

2028-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this clinical trial is to evaluate whether the use of an acellular dermal matrix (SureDerm) can improve cosmetic satisfaction and is safe in women with breast cancer undergoing breast-conserving surgery.

The main questions it aims to answer are:

1. Does the use of SureDerm improve patient-reported cosmetic satisfaction after breast-conserving surgery?
2. Is the use of SureDerm safe in terms of complication rates compared to standard surgery without SureDerm?

Researchers will compare patients receiving SureDerm during surgery with patients undergoing standard breast-conserving surgery without SureDerm to see if cosmetic results and safety differ between the groups.

Participants will:

* Undergo breast-conserving surgery, with or without SureDerm (assigned randomly)
* Receive standard postoperative radiotherapy
* Complete questionnaires about cosmetic satisfaction (Breast-Q) at baseline, 1 month, and 12 months after surgery
* Be followed for complications and cosmetic assessments by physicians

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Neoplasms Mastectomy, Segmental

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Parallel assignment with 1:1 randomization (ADM vs no ADM)
Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Breast-Conserving Surgery With SureDerm

Participants will undergo breast-conserving surgery with implantation of an acellular dermal matrix (SureDerm). All participants will also receive standard postoperative radiotherapy.

Group Type EXPERIMENTAL

Acellular Dermal Matrix (SureDerm BCS)

Intervention Type DEVICE

Participants in this arm will undergo breast-conserving surgery with placement of an acellular dermal matrix (SureDerm BCS). The device is implanted during surgery to provide soft tissue support and improve cosmetic outcomes. All participants will also receive standard postoperative radiotherapy.

Breast-Conserving Surgery Without SureDerm

Participants will undergo standard breast-conserving surgery without the use of acellular dermal matrix. All participants will also receive standard postoperative radiotherapy.

Group Type ACTIVE_COMPARATOR

Standard Breast-Conserving Surgery

Intervention Type PROCEDURE

Participants in this arm will undergo standard breast-conserving surgery without the use of acellular dermal matrix. This procedure involves removal of the breast tumor with preservation of most of the breast tissue. All participants will also receive standard postoperative radiotherapy.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Acellular Dermal Matrix (SureDerm BCS)

Participants in this arm will undergo breast-conserving surgery with placement of an acellular dermal matrix (SureDerm BCS). The device is implanted during surgery to provide soft tissue support and improve cosmetic outcomes. All participants will also receive standard postoperative radiotherapy.

Intervention Type DEVICE

Standard Breast-Conserving Surgery

Participants in this arm will undergo standard breast-conserving surgery without the use of acellular dermal matrix. This procedure involves removal of the breast tumor with preservation of most of the breast tissue. All participants will also receive standard postoperative radiotherapy.

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Acellular Dermal Matrix Lumpectomy

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Female patients aged 20 to 75 years
* Diagnosed with unilateral breast cancer (ICD-10 code: C50, D05) and treated with breast-conserving surgery
* Agreed to the use of acellular dermal matrix (ADM) during surgery
* Histologically confirmed primary breast cancer
* Patients who received neoadjuvant chemotherapy are eligible
* Planned to receive standard postoperative treatment, including adjuvant radiotherapy
* Voluntarily decided to participate in the study and provided written informed consent

Exclusion Criteria

* Evidence of distant metastasis
* Presence of infectious disease, autoimmune disease (e.g., specific rheumatologic disorders), or bleeding/coagulation disorders
* Known adverse reactions to all first-line antibiotics
* Suspected inflammatory infection of the breast prior to surgery
* Pregnant women at the time of enrollment
* Definite contraindications to the use of acellular dermal matrix
* Contraindications to radiotherapy
* Male patients
* History of another malignancy diagnosed within the past 5 years
* Patients deemed unsuitable for participation due to difficulty in data collection as judged by the investigator
* Patients unable to understand or complete the study questionnaires
Minimum Eligible Age

20 Years

Maximum Eligible Age

75 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Seoul St. Mary's Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Chang-Ik Yoon

Assistant Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea

Seoul, Seoul, South Korea

Site Status

Countries

Review the countries where the study has at least one active or historical site.

South Korea

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Chang Ik Yoon, MD, PhD

Role: CONTACT

+82-2-2258-6109

Jin Ah Lee, MD

Role: CONTACT

+82-2-2258-6333

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Chang Ik Yoon, MD, PhD

Role: primary

+82-2-2258-6109

References

Explore related publications, articles, or registry entries linked to this study.

Gorbunov SG, Gorelov AV, Kosorotikova AI. [Etiological structure of acute respiratory viral infections in children hospitalized in 1981-1999]. Zh Mikrobiol Epidemiol Immunobiol. 2001 Nov-Dec;(6):25-7. Russian.

Reference Type RESULT
PMID: 11881489 (View on PubMed)

Pusic AL, Klassen AF, Scott AM, Klok JA, Cordeiro PG, Cano SJ. Development of a new patient-reported outcome measure for breast surgery: the BREAST-Q. Plast Reconstr Surg. 2009 Aug;124(2):345-353. doi: 10.1097/PRS.0b013e3181aee807.

Reference Type RESULT
PMID: 19644246 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

XC25EIDV0042

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.